In last trading session, Karyopharm Therapeutics Inc (NASDAQ:KPTI) saw 0.85 million shares changing hands with its beta currently measuring 0.06. Company’s recent per share price level of $0.72 trading at $0.0 or 0.36% at ring of the bell on the day assigns it a market valuation of $90.68M. That closing price of KPTI’s stock is at a discount of -170.83% from its 52-week high price of $1.95 and is indicating a premium of 19.44% from its 52-week low price of $0.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.26 million shares which gives us an average trading volume of 935.36K if we extend that period to 3-months.

For Karyopharm Therapeutics Inc (KPTI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.57. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.25 in the current quarter.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) trade information

Upright in the green during last session for gaining 0.36%, in the last five days KPTI remained trading in the red while hitting it’s week-highest on Monday, 01/06/25 when the stock touched $0.72 price level, adding 13.25% to its value on the day. Karyopharm Therapeutics Inc’s shares saw a change of 6.25% in year-to-date performance and have moved -11.46% in past 5-day. Karyopharm Therapeutics Inc (NASDAQ:KPTI) showed a performance of -6.88% in past 30-days. Number of shares sold short was 19.79 million shares which calculate 24.61 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 85.6% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 14. It follows that stock’s current price would drop -316.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -316.67% for stock’s current value.

Karyopharm Therapeutics Inc (KPTI) estimates and forecasts

Statistics highlight that Karyopharm Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -25.33% of value to its shares in past 6 months, showing an annual growth rate of 24.80% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 4.70% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 38.2M for the same. And 2 analysts are in estimates of company making revenue of 39.2M in the next quarter. Company posted 33.75M and 33.13M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 16.79% during past 5 years.

Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s Major holders

Insiders are in possession of 6.20% of company’s total shares while institution are holding 48.24 percent of that, with stock having share float percentage of 51.43%. Investors also watch the number of corporate investors in a company very closely, which is 48.24% institutions for Karyopharm Therapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at KPTI for having 7.65 million shares of worth $6.64 million. And as of 2024-06-30, it was holding 6.6299 of the company’s outstanding shares.

The second largest institutional holder is PALO ALTO INVESTORS LP, which was holding about 5.1 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.4192 of outstanding shares, having a total worth of $4.43 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Explorer Fund, Inc. are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 3.42 shares of worth $2.46 million or 2.71% of the total outstanding shares. The later fund manager was in possession of 2.01 shares on Oct 31, 2024 , making its stake of worth around $1.44 million in the company or a holder of 1.59% of company’s stock.